Featured · Health
InBody sells the scale for the Ozempic era and refuses to pick a favorite drugmaker
US hospitals bought InBody's body-composition scanners at a 60%-plus clip in the first half of 2026, on one analyst's estimate, as obesity clinics add the muscle tracking the drugs demand. Founder Cha Ki-chul is declining exclusive pharma deals to stay the neutral instrument in every clinic.
· 3 min read


